These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved? Bhat S; Fujitani S; Potoski BA; Capitano B; Linden PK; Shutt K; Paterson DL Int J Antimicrob Agents; 2007 Nov; 30(5):458-62. PubMed ID: 17703923 [TBL] [Abstract][Full Text] [Related]
45. Bacteremia and fungemia in pediatric versus adult cancer patients after chemotherapy: comparison of etiology, risk factors and outcome. Krupova I; Kaiserova E; Foltinova A; Kovacicova G; Kiskova M; Krchnakova A; Kunova A; Trupl J; West D; Krcmery V J Chemother; 1998 Jun; 10(3):236-42. PubMed ID: 9669650 [TBL] [Abstract][Full Text] [Related]
46. Osteoarticular infection caused by MDR Pseudomonas aeruginosa: the benefits of combination therapy with colistin plus β-lactams. Ribera A; Benavent E; Lora-Tamayo J; Tubau F; Pedrero S; Cabo X; Ariza J; Murillo O J Antimicrob Chemother; 2015 Dec; 70(12):3357-65. PubMed ID: 26419763 [TBL] [Abstract][Full Text] [Related]
47. Clinical characteristics and risk factors for mortality in cefepime-resistant Pseudomonas aeruginosa bacteremia. Su TY; Ye JJ; Hsu PC; Wu HF; Chia JH; Lee MH J Microbiol Immunol Infect; 2015 Apr; 48(2):175-82. PubMed ID: 24064286 [TBL] [Abstract][Full Text] [Related]
48. Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study. Su TY; Ye JJ; Yang CC; Huang CT; Chia JH; Lee MH Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):52. PubMed ID: 28738848 [TBL] [Abstract][Full Text] [Related]
49. Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia. Park SY; Park HJ; Moon SM; Park KH; Chong YP; Kim MN; Kim SH; Lee SO; Kim YS; Woo JH; Choi SH BMC Infect Dis; 2012 Nov; 12():308. PubMed ID: 23157735 [TBL] [Abstract][Full Text] [Related]
50. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems. Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977 [TBL] [Abstract][Full Text] [Related]
51. Community-acquired Pseudomonas aeruginosa sepsis in previously healthy infants and children: analysis of forty-three episodes. Huang YC; Lin TY; Wang CH Pediatr Infect Dis J; 2002 Nov; 21(11):1049-52. PubMed ID: 12442028 [TBL] [Abstract][Full Text] [Related]
52. [Clinical analysis of Pseudomonas aeruginosa bacteremia]. Kumasaka K; Hosokawa N; Yanai M; Yagoshi M; Simoguchi K; Kawano K Rinsho Byori; 1999 Nov; 47(11):1064-9. PubMed ID: 10590685 [TBL] [Abstract][Full Text] [Related]
53. Different clinical presentation of community-onset bacteremia among neutropenic adults in the ED. Lee CC; Hsieh CC; Lee NY; Chan TY; Hong MY; Chi CH; Ko WC Am J Emerg Med; 2015 Jul; 33(7):907-12. PubMed ID: 25959847 [TBL] [Abstract][Full Text] [Related]
54. Clinical features and outcome of patients with community-acquired Pseudomonas aeruginosa bacteraemia. Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW Clin Microbiol Infect; 2005 May; 11(5):415-8. PubMed ID: 15819873 [TBL] [Abstract][Full Text] [Related]
55. Risk of developing pneumonia is enhanced by the combined traits of fluoroquinolone resistance and type III secretion virulence in respiratory isolates of Pseudomonas aeruginosa. Sullivan E; Bensman J; Lou M; Agnello M; Shriner K; Wong-Beringer A Crit Care Med; 2014 Jan; 42(1):48-56. PubMed ID: 23963124 [TBL] [Abstract][Full Text] [Related]
56. Risk factors of septic shock in patients with hematologic malignancies and Pseudomonas infections. Jeddi R; Ghédira H; Ben Amor R; Turki A; Kacem K; Ben Abdennebi Y; Ben Lakhal R; Aissaoui L; Ben Abid H; Bel Hadjali Z; Meddeb B Hematology; 2011 May; 16(3):160-5. PubMed ID: 21669056 [TBL] [Abstract][Full Text] [Related]
59. [Three cases of necrotizing pneumonia by pseudomonas aeruginosa infection in hematological malignancy, including dead and alive cases]. Imataki O; Tamai Y; Abe Y; Kusafuka K; Kawakami K Gan To Kagaku Ryoho; 2007 May; 34(5):793-7. PubMed ID: 17496460 [TBL] [Abstract][Full Text] [Related]
60. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Vidal F; Mensa J; Almela M; Martínez JA; Marco F; Casals C; Gatell JM; Soriano E; Jimenez de Anta MT Arch Intern Med; 1996 Oct; 156(18):2121-6. PubMed ID: 8862105 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]